Finally, we speculate that because the hallmarks of HGPS are present at lower levels in the vasculature and other tissues of aged-normal individuals33, NAT10 targeting might offer therapeutic opportunities in broader settings. The gene discussed is NAT10; the disease is Hutchinson-Gilford progeria syndrome.